Sera Prognostics, Inc., was founded in January 2008 to develop diagnostic tests for early prediction of preterm birth, preeclampsia and other pregnancy complications.
In collaboration with the National Institutes of Health Maternal Fetal Medicine Network, Sera’s scientific cofounders, Steven W. Graves, Ph.D., a professor in the department of Chemistry and Biochemistry at Brigham Young University and M. Sean Esplin, M.D., an associate professor and high-risk obstetrician at the University of Utah School of Medicine, identified biomarkers detectable from simple blood tests that can help predict the likelihood of preterm delivery and other pregnancy complications.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/01/11 | Series A | 19.3M | Unknown |